AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-84. (canceled)

85. (currently amended) A method for activating a Tγ9δ2 lymphocyte in vitro, comprising:

contacting in vitro a Tγ9δ2 lymphocyte with an effective amount of a compound comprising at least one phosphoepoxide group, said compound having a formula selected from the group consisting of

(a) a compound having the following formula:



(2)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20;

(b) a compound having the following formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20; and[[.]]

(c) a compound having the following formula:



(5)

wherein R1 is selected from among $-CH_3$ and CH_2CH_3,

Cat^+ is a cation, and

n is an integer between 2 and 20, and

R2 is a biomolecule.

86. (previously presented) The method according to claim 85, wherein said compound is brought into contact with a Tγ9δ2 lymphocyte in the presence of a T lymphocyte growth factor.

87. (previously presented) The method according to claim 85, wherein said T lymphocyte growth factor is IL-2.

88. (previously presented) The method according to claim 85, wherein said compound is introduced into a medium containing said Tγ9δ2 lymphocytes and cells.

89. (previously presented) The method according to claim 85, wherein said compound and said Tγ9δ2 lymphocyte are introduced into a medium that allows for T lymphocyte growth.

90-95. (canceled)

96. (previously presented) A compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20.

97. (currently amended) A compound of the formula:



(5)

wherein R1 is selected from among $-CH_3$ and CH_2CH_3,

Cat^+ is a cation,

n is an integer between 2 and 20, and

R2 is a biomolecule.



(14)



(15)



(11)



(8)



(13)





(20)

98. (currently amended) A composition comprising an excipient and a compound that can activate a Tγ9δ2 lymphocyte, wherein said compound is selected from the group consisting of:

a) a compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2-CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20; and

b) a compound of the formula:

~~a compound of the formula:~~



according to claim 97.

99. (previously presented) The composition according to claim 98, further comprising a pharmaceutically acceptable excipient.

100-102. (canceled)

103. (previously presented) The composition according to claim 98, wherein said compound is diluted in a sterile phosphate buffer at pH 7.

104. (previously presented) The composition according to claim 98, wherein said composition is in the form of a composition that can be topically administered.

105. (previously presented) The composition according to claim 98, further comprising primate Tγ9δ2 lymphocytes.

106. (previously presented) The composition according to claim 98, further comprising a T lymphocyte growth factor.

107-115. (canceled)

116. (previously presented) A compound of the formula:



(5)

wherein R1 is selected from among $-CH_3$ and $-CH_2-CH_3$,

Cat^+ is a cation,

n is an integer between 2 and 20, and

R2 is selected from the group consisting of a nucleoside and a phosphoepoxide.

117. (previously presented) A composition comprising an excipient and a compound that can activate Tγ9δ2 lymphocytes, wherein said compound is selected from the group consisting of

a) a compound of the formula:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20,

and

b) a compound of the formula:



(5)

wherein R1 is selected from among $-CH_3$ and $-CH_2CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20,

and R2 is selected from the group consisting of a nucleoside and a phosphoepoxide.

118. (previously presented) The method according to claim 85, wherein said compound is

a compound having a formula of:



(4)

wherein R1 is selected from among $-CH_3$ and $-CH_2-CH_3$,

Cat^+ is a cation, and

n is an integer between 2 and 20.

119. (cancelled).

120. (previously presented) The method according to claim 85, wherein said compound is a compound having the following formula:



(5)

wherein R1 is selected from among $-CH_3$ and CH_2CH_3,

Cat^+ is a cation, and

n is an integer between 2 and 20, and

R2 is a biomolecule.